David Jacoby is the SVP, Head of Clinical Development at Ultragenyx, specializing in rare genetic diseases. In his prior role at BioMarin, he led the successful registration of Brineura and Palynziq. An MD from the University of Pennsylvania, his expertise spans biologics, gene therapy, and antisense oligonucleotides for high-unmet-need disorders.
He led the team that achieved the successful registration of Brineura, a therapy for the CLN2 form of Battens disease, a rare and fatal pediatric neurodegenerative disorder.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.